Leg Ulcer Treatments Market Global Report 2026

The leg ulcer treatments market size has grown strongly in recent years. It will grow from $4.05 billion in 2025 to $4.36 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to rising prevalence of diabetes, increasing cases of peripheral vascular disease, limited access to advanced wound care solutions, growing hospital admissions for chronic wound conditions, and low awareness regarding early-stage ulcer treatment and management.

The leg ulcer treatments market size is expected to see strong growth in the next few years. It will grow to $5.9 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to the increasing burden of the aging population, rising demand for outpatient-based wound care services, growing emphasis on preventive vascular screening programs, expansion of home-based wound management practices, and continuous improvement in clinical guidelines for chronic ulcer treatment. Major trends include rising prevalence of chronic venous and diabetic ulcers, increasing incidence of impaired wound healing among elderly populations, growing diabetes-related complications leading to leg ulcers, a shift toward standardized evidence-based wound care protocols, and increasing adoption of compression therapy and debridement-based treatment approaches.

The increasing prevalence of chronic wounds is anticipated to drive the growth of the leg ulcer treatments market going forward. Chronic wounds are injuries that do not heal within the expected period, typically remaining open for more than three months. The prevalence of chronic wounds is increasing due to an aging population, as older adults are more prone to conditions that delay healing, such as diabetes, poor blood circulation, and weakened skin integrity. Leg ulcer treatments assist in managing chronic wounds by enhancing blood circulation, preventing and controlling infections, reducing inflammation, and supporting tissue regeneration through compression therapy, specialized wound dressings, and targeted medical care, which collectively promote consistent and effective healing. For instance, in November 2023, according to the National Health Service (NHS) England, a UK-based government department, between 01/10/2022 and 01/10/2023, a total of 193 inpatients were reported to have developed bed sores, pressure sores, or pressure ulcers during their hospital stay. Therefore, the increasing prevalence of chronic wounds is driving the growth of the leg ulcer treatments market.

Leading companies operating in the leg ulcer treatments market are focusing on developing innovative products, such as portable negative pressure wound therapy (NPWT) systems to improve healing outcomes, enhance patient mobility, and reduce long-term treatment costs associated with chronic venous and diabetic leg ulcers. NPWT systems are advanced wound-care devices that apply controlled, localized sub-atmospheric pressure to the wound bed using a sealed dressing connected to a compact pump and drainage canister. for example, in April 2024, Smith+Nephew plc, a UK-based medical technology company, launched the RENASYS EDGE Negative Pressure Wound Therapy System, an innovative home-care-focused device designed to support patients living with chronic wounds, including leg ulcers. The system is lightweight and compact, allowing it to be easily carried or worn by patients, and features a discreet canister that minimizes visibility while maintaining effective exudate management. It operates quietly to avoid disrupting daily activities, improving patient compliance and quality of life during long-term treatment. The device is widely used for managing chronic venous leg ulcers, diabetic foot ulcers, and other complex wounds, offering improved mobility, comfort, and healing efficiency compared to conventional dressing-based approaches.

In August 2023, Coloplast A/S, a Denmark-based healthcare company, acquired Kerecis for an undisclosed amount. Through this transaction, Coloplast A/S sought to reinforce its leadership in advanced wound care by integrating fish-skin-derived biologic graft technology into its existing portfolio, thereby enhancing its regenerative medicine and tissue repair offerings across chronic wound and surgical care applications. Kerecis is an Iceland-based medical device and biologics company focused on developing fish-skin graft products utilized for wound healing, tissue regeneration, and soft tissue repair in both chronic and acute wound settings.

Major companies operating in the leg ulcer treatments market are Cardinal Health Inc., Essity AB, Solventum Corporation, B. Braun Melsungen AG, Smith & Nephew plc, ConvaTec Group Plc, Mölnlycke Health Care AB, Coloplast A/S, Paul Hartmann AG, Winner Medical Co. Ltd., Integra LifeSciences Holdings Corporation, Lohmann & Rauscher International GmbH & Co. KG, Urgo Medical SAS, Organogenesis Holdings Inc., MiMedX Group Inc., DeRoyal Industries Inc., Advancis Medical Limited, MediWound Ltd., Triage Meditech Pvt. Ltd., Natrox Wound Care Ltd.

North America was the dominant region in the leg ulcer treatments market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in leg ulcer treatments report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leg ulcer treatments market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The leg ulcer treatments market consists of revenues earned by entities by providing services such as wound assessment, debridement procedures, compression therapy application, infection management, outpatient wound care services, home-based wound management, and chronic wound monitoring and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The leg ulcer treatments market also includes sales of advanced wound dressings, compression bandages, wound care devices, negative pressure wound therapy systems, topical treatment products, and related medical supplies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The leg ulcer treatments market research report is one of a series of new reports that provides leg ulcer treatments market statistics, including leg ulcer treatments industry global market size, regional shares, competitors with a leg ulcer treatments market share, detailed leg ulcer treatments market segments, market trends and opportunities, and any further data you may need to thrive in the leg ulcer treatments industry. This leg ulcer treatments market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.